Cardiex's new product launch in the US

Cardiex (ASX:CDX) has started pre-orders for its CONNEQT Arterial Health Assessment in the United States. The product features the CONNEQT Pulse vascular biometric monitor. This follows a successful waitlist campaign with over 20,000 sign-ups.

Overview of Cardiex's strategic US market entry

Cardiex Limited has commenced pre-orders for its CONNEQT Arterial Health Assessment in the United States, marking a significant step in its strategy to expand into broader healthcare markets. The phased rollout aims to manage demand effectively and enhance customer experience. CEO Craig Cooper anticipates that this will drive revenue growth. The CONNEQT Pulse offers advanced vascular health metrics, aiming to meet the increasing demand for comprehensive cardiovascular monitoring. Cardiex's products are grounded in its SphygmoCor® technology, focusing on improving vascular health and longevity. The company's strategic move into the US market highlights its ambition to leverage its technology for consumer health solutions, with further pre-order invitations planned in the coming weeks.

Executive insights on Cardiex's US expansion

This is a pivotal moment for Cardiex as we enter broader healthcare markets in the US. We expect this initiative to support our revenue growth.